{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T02:14:24Z","timestamp":1778897664373,"version":"3.51.4"},"reference-count":32,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T00:00:00Z","timestamp":1766448000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100016300","name":"Octapharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100016300","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","rpthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Research and Practice in Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.rpth.2025.103327","type":"journal-article","created":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T00:23:52Z","timestamp":1767140632000},"page":"103327","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Factor VIII and von Willebrand factor activity levels during long-term prophylaxis with wilate\u2014Analyses from the WIL-31 study"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9509-9415","authenticated-orcid":false,"suffix":"Jr.","given":"Robert F.","family":"Sidonio","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Boban","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Djambas Khayat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.rpth.2025.103327_bib1","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1056\/NEJMra1601561","article-title":"Von Willebrand\u2019s disease","volume":"375","author":"Leebeek","year":"2016","journal-title":"N Engl J Med"},{"issue":"Suppl 3","key":"10.1016\/j.rpth.2025.103327_bib2","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/hae.14970","article-title":"Diagnosis and treatment of von Willebrand disease in 2024 and beyond","volume":"30","author":"James","year":"2024","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2025.103327_bib3","doi-asserted-by":"crossref","DOI":"10.1177\/20406207211064064","article-title":"Prophylactic management of patients with von Willebrand disease","volume":"12","author":"Franchini","year":"2021","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.rpth.2025.103327_bib4","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1182\/bloodadvances.2020003264","article-title":"ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease","volume":"5","author":"Connell","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.rpth.2025.103327_bib5","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/jth.14343","article-title":"High levels of coagulation factors and venous thrombosis risk: strongest association for factor VIII and von Willebrand factor","volume":"17","author":"Rietveld","year":"2019","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2025.103327_bib6","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1182\/bloodadvances.2020003135","article-title":"Plasma levels of von Willebrand factor and future risk of incident venous thromboembolism","volume":"5","author":"Edvardsen","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.rpth.2025.103327_bib7","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1056\/NEJM200008173430702","article-title":"High plasma levels of factor VIII and the risk of recurrent venous thromboembolism","volume":"343","author":"Kyrle","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rpth.2025.103327_bib8","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1055\/s-0037-1613225","article-title":"Venous thromboembolism in von Willebrand disease","volume":"88","author":"Mannucci","year":"2002","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.rpth.2025.103327_bib9","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1080\/10245330500345710","article-title":"Thrombotic complications in von Willebrand disease","volume":"11","author":"Franchini","year":"2006","journal-title":"Hematology"},{"key":"10.1016\/j.rpth.2025.103327_bib10","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1111\/hae.12955","article-title":"Practical aspects of factor concentrate use in patients with von Willebrand disease undergoing invasive procedures: a European survey","volume":"22","author":"Windyga","year":"2016","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2025.103327_bib11","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1365-2516.2007.01643.x","article-title":"von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA)","volume":"14","author":"Nichols","year":"2008","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2025.103327_bib12","first-page":"117","article-title":"Evidence-based recommendations on the treatment of von Willebrand disease in Italy","volume":"7","author":"Mannucci","year":"2009","journal-title":"Blood Transfus"},{"key":"10.1016\/j.rpth.2025.103327_bib13","doi-asserted-by":"crossref","first-page":"667","DOI":"10.3324\/haematol.2012.077263","article-title":"Principles of care for the diagnosis and treatment of von Willebrand disease","volume":"98","author":"Castaman","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.rpth.2025.103327_bib14","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1182\/bloodadvances.2023011742","article-title":"Von Willebrand factor\/factor VIII concentrate (Wilate) prophylaxis in children and adults with von Willebrand disease","volume":"8","author":"Sidonio","year":"2024","journal-title":"Blood Adv"},{"key":"10.1016\/j.rpth.2025.103327_bib15","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s11239-008-0253-7","article-title":"Antithrombotic prophylaxis in patients with von Willebrand disease undergoing major surgery: when is it necessary?","volume":"28","author":"Franchini","year":"2009","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.rpth.2025.103327_bib16","doi-asserted-by":"crossref","first-page":"e404","DOI":"10.1111\/hae.12498","article-title":"Thromboembolic incidence with transiently elevated levels of coagulation factors in patients with von Willebrand disease treated with VWF: FVIII concentrate during surgery","volume":"20","author":"Gill","year":"2014","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2025.103327_bib17","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1111\/j.1365-2516.2011.02534.x","article-title":"von Willebrand factor\/factor VIII concentrate (Humate-P\u00ae) for management of elective surgery in adults and children with von Willebrand disease","volume":"17","author":"Gill","year":"2011","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2025.103327_bib18","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1111\/j.1538-7836.2007.02588.x","article-title":"Surgical Study, Group. von Willebrand factor\/factor VIII concentrate (Haemate\u00ae P) dosing based on pharmacokinetics: a prospective multicenter trial in elective surgery","volume":"5","author":"Lethagen","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2025.103327_bib19","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/hae.13451","article-title":"Analysis of current perioperative management with Haemate\u00ae P\/Humate P\u00ae in von Willebrand disease: identifying the need for personalized treatment","volume":"24","author":"Hazendonk","year":"2018","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2025.103327_bib20","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1182\/blood.V99.2.450","article-title":"Treatment of von Willebrand disease with a high-purity factor VIII\/von Willebrand factor concentrate: a prospective, multicenter study","volume":"99","author":"Mannucci","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2025.103327_bib21","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/jth.14313","article-title":"Phase 3 study of recombinant von Willebrand factor in patients with severe von Willebrand disease who are undergoing elective surgery","volume":"17","author":"Peyvandi","year":"2019","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2025.103327_bib22","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1182\/blood.2021014810","article-title":"Recombinant von Willebrand factor prophylaxis in patients with severe von Willebrand disease: phase 3 study results","volume":"140","author":"Leebeek","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2025.103327_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2019.04.001","article-title":"Evolution of replacement therapy for von Willebrand disease: from plasma fraction to recombinant von Willebrand factor","volume":"38","author":"Peyvandi","year":"2019","journal-title":"Blood Rev"},{"key":"10.1016\/j.rpth.2025.103327_bib24","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1111\/hae.15079","article-title":"Efficacy of a 1:1 ratio VWF\/FVIII concentrate in patients with von Willebrand disease","volume":"30","author":"Kuppens","year":"2024","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2025.103327_bib25","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/hae.13106","article-title":"Efficacy and safety of a VWF\/FVIII concentrate (wilate\u00ae) in inherited von Willebrand disease patients undergoing surgical procedures","volume":"23","author":"Srivastava","year":"2017","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2025.103327_bib26","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1111\/hae.12237","article-title":"Efficacy and safety of Wilate in paediatric VWD patients under 6 years of age\u2014results of a prospective multicentre clinical study including recovery information","volume":"19","author":"Nowak-G\u00f6ttl","year":"2013","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2025.103327_bib27","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1160\/TH10-10-0631","article-title":"Efficacy and safety of a new generation von Willebrand factor\/factor VIII concentrate (Wilate\u00ae) in the management of perioperative haemostasis in von Willebrand disease patients undergoing surgery","volume":"105","author":"Windyga","year":"2011","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.rpth.2025.103327_bib28","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1111\/hae.12497","article-title":"Wilate use in 47 children with von Willebrand disease: the North London paediatric haemophilia network experience","volume":"21","author":"Khair","year":"2015","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2025.103327_bib29","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1160\/TH11-02-0057","article-title":"The pharmacokinetic diversity of two von Willebrand factor (VWF)\/factor VIII (FVIII) concentrates in subjects with congenital von Willebrand disease. Results from a prospective, randomised crossover study","volume":"106","author":"Kessler","year":"2011","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.rpth.2025.103327_bib30","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.biologicals.2005.11.010","article-title":"Characterisation of a novel high-purity, double virus inactivated von Willebrand Factor and Factor VIII concentrate (Wilate\u00ae)","volume":"34","author":"Stadler","year":"2006","journal-title":"Biologicals"},{"key":"10.1016\/j.rpth.2025.103327_bib31","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1182\/bloodadvances.2020003891","article-title":"Population pharmacokinetics of the von Willebrand factor-factor VIII interaction in patients with von Willebrand disease","volume":"5","author":"Bukkems","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.rpth.2025.103327_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2025.103221","article-title":"Individualizing dosing frequency may improve the efficacy of prophylaxis in patients with von Willebrand disease\u2014a WIL-31 sub-analysis","volume":"9","author":"Sidonio","year":"2025","journal-title":"Res Pract Thromb Haemost"}],"container-title":["Research and Practice in Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S247503792500651X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S247503792500651X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T01:55:57Z","timestamp":1778896557000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S247503792500651X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S247503792500651X"],"URL":"https:\/\/doi.org\/10.1016\/j.rpth.2025.103327","relation":{},"ISSN":["2475-0379"],"issn-type":[{"value":"2475-0379","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Factor VIII and von Willebrand factor activity levels during long-term prophylaxis with wilate\u2014Analyses from the WIL-31 study","name":"articletitle","label":"Article Title"},{"value":"Research and Practice in Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rpth.2025.103327","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}],"article-number":"103327"}}